Omicron

SAGE no longer recommends annual COVID-19 vaccine boosters for healthy adults under 60 years of age after they have received both…

The company said its independently developed mRNA vaccine SYS6006 targets some major Omicron variants and its booster dose showed…

The research, published in the Canadian Medical Association Journal, aimed to evaluate the effectiveness of paxlovid, a…

The Canadian government had entered into a supply deal with the company last year for supply of its COVID vaccine for 2022 and…

A team of researchers, including those from the German Primate Center (DPZ)-Leibniz Institute for Primate Research in Germany,…

The company's vaccine, based on an earlier strain of the virus, has not yet been authorised in the US, and is currently under FDA…

The vaccine targets the beta variant – first identified in South Africa – as well as the original Wuhan strain of the virus

Researchers at King's College London found the odds of developing long COVID after infection were 20 per cent to 50 per cent lower…

The study was conducted from 11 January to 21 February 2022 involving over 1,000 patients in Moscow

With the announcement, Abogen joins Pfizer/BioNTech and Moderna in trialling candidates modified specifically against Omicron